{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T08:48:26Z","timestamp":1768985306637,"version":"3.49.0"},"reference-count":75,"publisher":"Bentham Science Publishers Ltd.","issue":"5","funder":[{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","award":["1072"],"award-info":[{"award-number":["1072"]}],"id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CHR"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Hepatitis C virus (HCV) acts in the host as a complicated mixture of related\nvariants with the potency to genetically escape host immune responses. Direct acting antivirals\n(DAAs) have been approved for HCV treatment with shorter duration, better cure rates and lower\nside effects. However, naturally occurring resistance associated substitutions (RASs) create some\nobstacles to this antiviral therapy success.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>In this study, we aimed at the determination of the naturally occurring NS3\/4A RASs in\nHCV\/human immunodeficiency virus (HIV)infected patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A total of 120 DAA-na\u00efve HCV-HIV co-infected patients were included. HCV\nNS3\/4Agenome region was amplified with PCR and mutation analysis was performed by Sanger\nsequencing technique. The amino acid sequence diversity of the region was analyzed using\ngeno2pheno HCV.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Phylogenetic analysis showed that 73 cases were infected by 3a and 47 subjects by subtype1a.\nThe overall RASs among studied subjects were observed in 6 (5%) individuals from 120\nstudied cases who were infected with HCV 1a. V36M\/L, Q80L, S122G\/L, R155T\/G, A156S,\nD168Y\/N and S174A\/N\/T mutations were detected in this study.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> Although the prevalence of RASs was totally low in this study, the presence of several\ncases of double and triple mutants among this population suggests prior evaluation of protease inhibitors\nrelated mutations before initiation of standard treatment and also an investigation on a\nlarge population could be of high value.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1566523221666210707142838","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T03:53:06Z","timestamp":1625802786000},"page":"391-397","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prevalence of Naturally Occurring Resistance Associated Substitutions in NS3\/4AProtease Inhibitors in Iranian HCV\/HIV Infected Patients"],"prefix":"10.2174","volume":"19","author":[{"given":"Kazem","family":"Baesi","sequence":"first","affiliation":[{"name":"Hepatitis & AIDS Dept., Pasteur Institute of Iran, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Akbar","family":"Velayati","sequence":"additional","affiliation":[{"name":"Masih Daneshvari Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoumeh Farrokh","family":"Ashtiani","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, Tehran University of Medical Sciences, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal","family":"Fakhredini","sequence":"additional","affiliation":[{"name":"Iranian Research Center for HIV\/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Banifazl","sequence":"additional","affiliation":[{"name":"Iranian Society for Support of Patients with Infectious Disease, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona Sadat","family":"Larijani","sequence":"additional","affiliation":[{"name":"Clinical Research Dept., Pasteur Institute of Iran, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parya","family":"Basimi","sequence":"additional","affiliation":[{"name":"Hepatitis & AIDS Dept., Pasteur Institute of Iran, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amitis","family":"Ramezani","sequence":"additional","affiliation":[{"name":"Clinical Research Dept., Pasteur Institute of Iran, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.7754\/Clin.Lab.2017.170308","volume":"63","author":"Larijani M.S.","year":"2017","unstructured":"Larijani M.S.; Sadat S.M.; Nikbin M.; Mohajel N.; Interleukin 20 gene polymorphism (rs1518108) is not associated with sustained virological response in Iranian patients with hepatitis C virus infection. Clin Lab 2017,63(9),1431-1437","journal-title":"Clin Lab"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7754\/Clin.Lab.2015.150724","volume":"62","author":"Larijani M.S.","year":"2016","unstructured":"Larijani M.S.; Sadat S.M.; Nikbin M.; Talebi S.S.; Javadi F.; Mohajel N.; Bolhassani A.; Daneshvar M.; Aghasadeghi M.R.; Pouriayevali M.H.; Mapar M.; Correlation Study Between IL-28B Gene Polymorphism (rs8099917SNP) and sustained virological response in Iranian patients with chronic hepatitis C. Clin Lab 2016,62(3),417-423","journal-title":"Clin Lab"},{"key":"ref=3","author":"Hepatitis C.","year":"2019","unstructured":"Hepatitis C.; World Health Organization  xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c2019"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jhep.2016.07.035","volume":"65","author":"Bukh J.","year":"2016","unstructured":"Bukh J.; The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. J Hepatol 2016,65(1)(Suppl.),S2-S21","journal-title":"J Hepatol"},{"key":"ref=5","first-page":"67","volume":"19","author":"Sadat-Larijani M.","year":"2015","unstructured":"Sadat-Larijani M.; Nikbin M.; Bakhshi-Khaniki G.R.; Talebi S.; Aghasadeghi M.R.; Sadat S.M.; Relationship between the IL28B gene-related single-nucleotide polymorphism of rs8099917 and susceptibility to hepatitis C infection in Iranian population. Feyz journal of kashan university of medical sciences 2015,19(1),67-75","journal-title":"Feyz journal of kashan university of medical sciences"},{"key":"ref=6","first-page":"3923","volume":"17","author":"Larijani M.S.","year":"2016","unstructured":"Larijani M.S.; Bahiraei N.; Nikbin M.; Mohajel N.; Rad L.N.; Baghbani F.; Mapar M.; Sadat S.M.; Lack of tnf-\u03b1 gene polymorphism (rs1799724) association with sustained virological response in Iranian patients with chronic hcv infection. Asian pac j cancer prev 2016,17(8),3923-3927","journal-title":"Asian pac j cancer prev"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.3748\/wjg.v13.i17.2406","volume":"13","author":"Dubuisson J.","year":"2007","unstructured":"Dubuisson J.; Hepatitis C virus proteins. World J Gastroenterol 2007,13(17),2406-2415","journal-title":"World J Gastroenterol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12985-015-0450-x","volume":"12","author":"Kumthip K.","year":"2015","unstructured":"Kumthip K.; Maneekarn N.; The role of HCV proteins on treatment outcomes. Virol J 2015,12(1),217","journal-title":"Virol J"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.7754\/Clin.Lab.2015.150807","volume":"62","author":"Larijani M.S.","year":"2016","unstructured":"Larijani M.S.; Rad L.N.; Nikbin M.; Bahiraei N.; Javadi F.; Daneshvar M.; Aghasadeghi M.R.; Rahimi P.; Siadat S.D.; Zabihollahi R.; Sadat S.M.; Impact of TGF-\u03b21 Gene Polymorphism (rs1800469) on treatment response to pegylated interferon\/ribavirin in Iranian patients with hepatitis C. Clin Lab 2016,62(4),609-614","journal-title":"Clin Lab"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1046\/j.1365-2893.1999.t01-1-6120131.x","volume":"6","author":"G\u00f3mez J.","year":"1999","unstructured":"G\u00f3mez J.; Martell M.; Quer J.; Cabot B.; Esteban J.I.; Hepatitis C viral quasispecies. J Viral Hepat 1999,6(1),3-16","journal-title":"J Viral Hepat"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"20310","DOI":"10.1038\/srep20310","volume":"6","author":"Chen Z.W.","year":"2016","unstructured":"Chen Z.W.; Li H.; Ren H.; Hu P.; Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Sci Rep 2016,6(1),20310","journal-title":"Sci Rep"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrgastro.2017.106","volume":"14","author":"Grebely J.","year":"2017","unstructured":"Grebely J.; Hajarizadeh B.; Dore G.J.; Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nat rev gastroenterol hepatol 2017,14(11),641-651","journal-title":"Nat rev gastroenterol hepatol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13027-016-0099-0","volume":"11","author":"Petruzziello A.","year":"2016","unstructured":"Petruzziello A.; Marigliano S.; Loquercio G.; Cacciapuoti C.; Hepatitis C virus (HCV) genotypes distribution: an epidemiological up- date in Europe. Infect Agent Cancer 2016,11,53-53","journal-title":"Infect Agent Cancer"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","volume":"22","author":"Petruzziello A.","year":"2016","unstructured":"Petruzziello A.; Marigliano S.; Loquercio G.; Cozzolino A.; Cacciapuoti C.; Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol 2016,22(34),7824-7840","journal-title":"World J Gastroenterol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"10790","DOI":"10.3748\/wjg.v21.i38.10790","volume":"21","author":"Taherkhani R.","year":"2015","unstructured":"Taherkhani R.; Farshadpour F.; Epidemiology of hepatitis C virus in Iran. World J Gastroenterol 2015,21(38),10790-10810","journal-title":"World J Gastroenterol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"e22915","DOI":"10.5812\/hepatmon.22915","volume":"14","author":"Khodabandehloo M.","year":"2014","unstructured":"Khodabandehloo M.; Roshani D.; Prevalence of hepatitis C virus genotypes in Iranian patients: A systematic review and meta-analysis. Hepat Mon 2014,14(12),e22915-e22915","journal-title":"Hepat Mon"},{"key":"ref=17","year":"2018","unstructured":"Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. IGO, L C B-N-S, Ed WHO  xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c#:~:text=The%20goal%20of%20hepatitis%20C,absence%20or%20presence%20of%20cirrhosis2018","journal-title":"IGO, L C B-N-S, Ed WHO"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.bcp.2014.04.005","volume":"89","author":"De Clercq E.","year":"2014","unstructured":"De Clercq E.; Current race in the development of DAAs (direct-acting antivirals) against HCV. Biochem Pharmacol 2014,89(4),441-452","journal-title":"Biochem Pharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cld.2019.04.003","volume":"23","author":"Abdelaal R.","year":"2019","unstructured":"Abdelaal R.; Yanny B.; El Kabany M.; HBV\/HCV Coinfection in the Era of HCV-DAAs. Clin Liver Dis 2019,23(3),463-472","journal-title":"Clin Liver Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"908","DOI":"10.5604\/01.3001.0012.7191","volume":"17","author":"Gonz\u00e1lez-Aldaco K.","year":"2018","unstructured":"Gonz\u00e1lez-Aldaco K.; Torres-Reyes L.A.; Ojeda-Granados C.; Jos\u00e9-\u00c1brego A.; Fierro N.A.; Rom\u00e1n S.; Immunometabolic effect of cholesterol in hepatitis C infection: Implications in clinical management and antiviral therapy. Ann Hepatol 2018,17(6),908-919","journal-title":"Ann Hepatol"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.6064\/2012\/478631","volume":"2012","author":"Karayiannis P.","year":"2012","unstructured":"Karayiannis P.; Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) 2012,2012","journal-title":"Scientifica (Cairo)"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.aohep.2019.04.004","volume":"18","author":"Lozano-Sep\u00falveda S.A.","year":"2019","unstructured":"Lozano-Sep\u00falveda S.A.; Rinc\u00f3n-Sanchez A.R.; Rivas-Estilla A.M.; Antioxidants benefits in hepatitis C infection in the new DAAs era. Ann Hepatol 2019,18(3),410-415","journal-title":"Ann Hepatol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.4254\/wjh.v7.i24.2543","volume":"7","author":"Fung J.","year":"2015","unstructured":"Fung J.; Era of direct acting antivirals in chronic hepatitis C: Who will benefit? World J Hepatol 2015,7(24),2543-2550","journal-title":"World J Hepatol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.20517\/2394-5079.2018.94","volume":"4","author":"Franco R.A.","year":"2018","unstructured":"Franco R.A.; Galbraith J.W.; Overton E.T.; Saag M.S.; Direct-acting antivirals and chronic hepatitis C: towards elimination. Hepatoma Res 2018,4,74","journal-title":"Hepatoma Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/S0140-6736(18)32326-2","volume":"393","author":"Holmes J.A.","year":"2019","unstructured":"Holmes J.A.; Rutledge S.M.; Chung R.T.; Direct-acting antiviral treatment for hepatitis C. Lancet 2019,393(10179),1392-1394","journal-title":"Lancet"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"6017","DOI":"10.1128\/AAC.00932-15","volume":"59","author":"Berger K.L.","year":"2015","unstructured":"Berger K.L.; Scherer J.; Ranga M.; Sha N.; Stern J.O.; Quinson A-M.; Kukolj G.; Baseline polymorphisms and emergence of drug resistance in the NS3\/4A protease of hepatitis C virus genotype 1 following treatment with faldaprevir and pegylated interferon alpha 2a\/ribavirin in phase 2 and phase 3 studies. Antimicrob agents chemother 2015,59(10),6017-6025","journal-title":"Antimicrob agents chemother"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.clinre.2019.01.011","volume":"43","author":"Ramezani A.","year":"2019","unstructured":"Ramezani A.; Baesi K.; Banifazl M.; Mohraz M.; Khorvash F.; Yaran M.; Tabarsi P.; Dalirrooyfard A.H.; Motevalli F.; Bavand A.; Aghakhani A.; Naturally occurring ns5a and ns5b resistant associated substitutions in HCV and HCV\/HIV patients in Iranian population. Clin Res Hepatol Gastroenterol 2019,43(5),594-602","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"e40959","DOI":"10.5812\/hepatmon.guideline","volume":"16","author":"Alavian S.M.","year":"2016","unstructured":"Alavian S.M.; Hajarizadeh B.; Bagheri Lankarani K.; Sharafi H.; Ebrahimi Daryani N.; Merat S.; Mohraz M.; Mardani M.; Fattahi M.R.; Poustchi H.; Nikbin M.; Nabavi M.; Adibi P.; Ziaee M.; Behnava B.; Rezaee-Zavareh M.S.; Colombo M.; Massoumi H.; Bizri A.R.; Eghtesad B.; Amiri M.; Namvar A.; Hesamizadeh K.; Malekzadeh R.; Recommendations for the clinical management of hepatitis c in Iran: A consensus-based national guideline. Hepat Mon 2016,16(8),e40959-e40959","journal-title":"Hepat Mon"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142543","volume":"10","author":"Chen M.","year":"2015","unstructured":"Chen M.; Ma Y.; Chen H.; Luo H.; Dai J.; Song L.; Yang C.; Mei J.; Yang L.; Dong L.; Jia M.; Lu L.; multiple introduction and naturally occuring drug resistance of HCV among HIV-infected intravenous drug users in Yunnan: An origin of China\u2019s HIV\/HCV Epidemics. PLoS One 2015,10(11)","journal-title":"PLoS One"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"12426","DOI":"10.1074\/jbc.RA120.013455","volume":"295","author":"Tallorin L.","year":"2020","unstructured":"Tallorin L.; Villareal V.A.; Hsia C-Y.; Rodgers M.A.; Burri D.J.; Pfeil M-P.; Llopis P.M.; Lindenbach B.D.; Yang P.L.; Hepatitis C virus NS3-4A protease regulates the lipid environment for RNA replication by cleaving host enzyme 24-dehydrocholesterol reductase. J biol chem 2020,295(35),12426-12436","journal-title":"J biol chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s11262-020-01776-y","volume":"56","author":"El-Tahan R.R.","year":"2020","unstructured":"El-Tahan R.R.; Ghoneim A.M.; Zaghloul H.; Dissection of two drug- targeted regions of Hepatitis C virus subtype 4a infecting Egyptian patients. Virus Genes 2020,56(5),564-581","journal-title":"Virus Genes"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.3390\/v2081752","volume":"2","author":"Chatel-Chaix L.","year":"2010","unstructured":"Chatel-Chaix L.; Baril M.; Lamarre D.; Hepatitis C.; Hepatitis C Virus NS3\/4A Protease Inhibitors: A light at the end of the tunnel. Viruses 2010,2(8),1752-1765","journal-title":"Viruses"},{"key":"ref=33","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/467869","volume":"2013","author":"Salam K.A.","year":"2013","unstructured":"Salam K.A.; Akimitsu N.; Hepatitis C.; Hepatitis C virus NS3 inhibitors: Current and future perspectives. BioMed res int 2013,2013","journal-title":"BioMed res int"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"16999","DOI":"10.1021\/acsomega.9b02491","volume":"4","author":"Meewan I.","year":"2019","unstructured":"Meewan I.; Zhang X.; Roy S.; Ballatore C.; O\u2019Donoghue A.J.; Schooley R.T.; Abagyan R.; Discovery of new inhibitors of hepatitis C Virus NS3\/4A Protease and Its D168A Mutant. ACS Omega 2019,4(16),16999-17008","journal-title":"ACS Omega"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"16017","DOI":"10.1038\/s41598-017-15987-1","volume":"7","author":"Paolucci S.","year":"2017","unstructured":"Paolucci S.; Premoli M.; Novati S.; Gulminetti R.; Maserati R.; Barbarini G.; Sacchi P.; Piralla A.; Sassera D.; De Marco L.; Girello A.; Mondelli M.U.; Baldanti F.; Baseline and breakthrough resistance mutations in HCV patients failing DAAs. Sci Rep 2017,7(1),16017","journal-title":"Sci Rep"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1007\/s00705-018-3920-9","volume":"163","author":"Moreira R.C.","year":"2018","unstructured":"Moreira R.C.; de Torres Santos A.P.; Lisboa-Neto G.; Mendes-Corr\u00eaa M.C.J.; Lemos M.F.; Malta F.M.; Santana R.A.F.; Dastoli G.T.F.; de Castro V.F.D.; Pinho J.R.R.; Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3\/NS4A protease inhibitors in S\u00e3o Paulo state. Arch Virol 2018,163(10),2757-2764","journal-title":"Arch Virol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","volume":"64","author":"Sarrazin C.","year":"2016","unstructured":"Sarrazin C.; The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 2016,64(2),486-504","journal-title":"J Hepatol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"W271","DOI":"10.1093\/nar\/gky349","volume":"46","author":"D\u00f6ring M.","year":"2018","unstructured":"D\u00f6ring M.; B\u00fcch J.; Friedrich G.; Geno2pheno[ngs-freq]: A genotypic interpretation system for identifying viral drug resistance using next-generation sequencing data. Nucleic Acids Res 2018,46(W1),W271-W277","journal-title":"Nucleic Acids Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","year":"2018","unstructured":"EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018,69(2),461-511","journal-title":"J Hepatol"},{"key":"ref=40","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.37011","volume":"16","author":"Kadjbaf D.","year":"2016","unstructured":"Kadjbaf D.; Keshvari M.; Alavian S.M.; Pouryasin A.; Behnava B.; Salimi S.; Mehrnoush L.; Karimi Elizee P.; Sharafi H.; The Prevalence of hepatitis c virus core amino acid 70 substitution and genotypes of polymorphisms near the ifnl3 gene in Iranian patients with chronic hepatitis C. Hepat Mon 2016,16(6)","journal-title":"Hepat Mon"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/jmv.24255","volume":"87","author":"Yoshimi S.","year":"2015","unstructured":"Yoshimi S.; Imamura M.; Murakami E.; Hiraga N.; Tsuge M.; Kawakami Y.; Aikata H.; Abe H.; Hayes C.N.; Sasaki T.; Ochi H.; Chayama K.; Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J Med Virol 2015,87(11),1913-1920","journal-title":"J Med Virol"},{"key":"ref=42","unstructured":"AASLD-IDSA, HCV Guidance. Recommendations for testing, managing, and treating hepatitis. Recommendations for testing, managing, and treating hepatitis Available from:  xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"www.hcvguidelines.org\">www.hcvguidelines.org","journal-title":"Recommendations for testing, managing, and treating hepatitis"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/liv.12061","volume":"33","author":"Clark V.C.","year":"2013","unstructured":"Clark V.C.; Peter J.A.; Nelson D.R.; New therapeutic strategies in HCV: Second-generation protease inhibitors. Liver Int 2013,33,80-84","journal-title":"Liver Int"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/ofid\/ofz360.427","volume":"6","author":"Saba N.","year":"2019","unstructured":"Saba N.; Chirch L.; Banks S. H.; Wu G.; Einstein M.; Efficacy of second-generation direct acting antivirals in the setting of HCV\/HIV Co-infection and Cirrhosis: A review of real-world treatment experiences. Open forum infectious diseases 2019,6,186-187","journal-title":"Open forum infectious diseases"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2147\/IJGM.S283910","volume":"14","author":"Gao L.H.","year":"2021","unstructured":"Gao L.H.; Nie Q.H.; Zhao X.T.; Drug-drug interactions of newly approved direct-acting antiviral agents in patients with hepatitis C. Int J Gen Med 2021,14,289-301","journal-title":"Int J Gen Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/jvh.13115","volume":"26","author":"Belperio P.S.","year":"2019","unstructured":"Belperio P.S.; Shahoumian T.A.; Loomis T.P.; Backus L.I.; Real-world effectiveness of sofosbuvir\/velpatasvir\/voxilaprevir in 573 direct-acting antiviral experienced hepatitis c patients. J Viral Hepat 2019,26(8),980-990","journal-title":"J Viral Hepat"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1093\/cid\/ciz022","volume":"69","author":"Gane E.","year":"2019","unstructured":"Gane E.; Poordad F.; Zadeikis N.; Valdes J.; Lin C-W.; Liu W.; Asatryan A.; Wang S.; Stedman C.; Greenbloom S.; Nguyen T.; Elkhashab M.; W\u00f6rns M-A.; Tran A.; Mulkay J-P.; Setze C.; Yu Y.; Pilot-Matias T.; Porcalla A.; Mensa F.J.; Safety and pharmacokinetics of glecaprevir\/pibrentasvir in adults with chronic genotype 1-6 hepatitis c virus infections and compensated liver disease. Clin Infect Dis 2019,69(10),1657-1664","journal-title":"Clin Infect Dis"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1021\/acs.jmedchem.7b00426","volume":"60","author":"Matthew A.N.","year":"2017","unstructured":"Matthew A.N.; Zephyr J.; Hill C.J.; Jahangir M.; Newton A.; Petropoulos C.J.; Huang W.; Kurt-Yilmaz N.; Schiffer C.A.; Ali A.; Hepatitis C.; Hepatitis C virus ns3\/4a protease inhibitors incorporating flexible p2 quinoxalines target drug resistant viral variants. J Med Chem 2017,60(13),5699-5716","journal-title":"J Med Chem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.str.2018.07.004","volume":"26","author":"Matthew A.N.","year":"2018","unstructured":"Matthew A.N.; Leidner F.; Newton A.; Petropoulos C.J.; Huang W.; Ali A.; KurtYilmaz N.; Schiffer C.A.; molecular mechanism of resistance in a clinically significant double-mutant variant of hcv ns3\/4a protease. Structure 2018,26(10),1360-1372.e5","journal-title":"Structure"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/10409238.2019.1568962","volume":"54","author":"\u00d6zen A.","year":"2019","unstructured":"\u00d6zen A.; Prachanronarong K.; Matthew A.N.; Soumana D.I.; Schiffer C.A.; Resistance outside the substrate envelope: hepatitis C NS3\/4A protease inhibitors. Crit Rev Biochem Mol Biol 2019,54(1),11-26","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"5328","DOI":"10.3390\/v7102876","volume":"7","author":"Chayama K.","year":"2015","unstructured":"Chayama K.; Hayes C.N.; HCV drug resistance challenges in Japan: The role of pre-existing variants and emerging resistant strains in direct acting antiviral therapy. Viruses 2015,7(10),5328-5342","journal-title":"Viruses"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1053\/j.gastro.2016.10.017","volume":"152","author":"Komatsu T.E.","year":"2017","unstructured":"Komatsu T.E.; Boyd S.; Sherwat A.; Tracy L.; Naeger L.K.; O\u2019Rear J.J.; Harrington P.R.; Regulatory analysis of effects of hepatitis C virus ns5a polymorphisms on efficacy of elbasvir and grazoprevir. Gastroenterology 2017,152(3),586-597","journal-title":"Gastroenterology"},{"key":"ref=53","first-page":"17","volume":"73","author":"Sorbo M. C.","year":"2018","unstructured":"Sorbo M. C.; Cento V.; Di Maio V. C.; Howe A. Y. M.; Garcia F.; Perno C. F.; Ceccherini-Silberstein F.; C virus drug resistance associated substitutions and their clinical relevance. reviews and commentaries in antimicrobial and anticancer chemotherapy 2018,73,17-39","journal-title":"reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40265-018-0895-5","volume":"78","author":"Heo Y.A.","year":"2018","unstructured":"Heo Y.A.; Deeks E.D.; Sofosbuvir\/Velpatasvir\/Voxilaprevir: A review in chronic hepatitis c. Drugs 2018,78(5),577-587","journal-title":"Drugs"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.jfma.2020.06.013","volume":"119","author":"Liu C-H.","year":"2020","unstructured":"Liu C-H.; Su T-H.; Liu C-J.; Chen P-J.; Chen D-S.; Kao J-H.; Sofosbuvir\/velpatasvir\/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan. J Formos Med Assoc 2020,119(12),1871-1875","journal-title":"J Formos Med Assoc"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"e01844","DOI":"10.1128\/JCM.01844-18","volume":"57","author":"Han B.","year":"2019","unstructured":"Han B.; Parhy B.; Lu J.; Hsieh D.; Camus G.; Martin R.; Svarovskaia E.S.; Mo H.; Dvory-Sobol H.; Dvory-Sobol H.; In vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3\/4A Inhibitor Voxilaprevir. J clin microbiol 2019,57(4),e01844-e18","journal-title":"J clin microbiol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11901-017-0328-z","volume":"16","author":"Hill L.A.","year":"2017","unstructured":"Hill L.A.; Wyles D.L.; Future Paradigms of HCV management with resistance testing. Curr hepatol rep 2017,16(1),1-11","journal-title":"Curr hepatol rep"},{"key":"ref=58","first-page":"Doc08","volume":"5","author":"de Leuw P.","year":"2017","unstructured":"de Leuw P.; Stephan C.; Protease inhibitors for the treatment of hepatitis C virus infection. GMS Infect Dis 2017,5,Doc08-Doc08","journal-title":"GMS Infect Dis"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.clinre.2019.02.009","volume":"43","author":"Costa V.D.","year":"2019","unstructured":"Costa V.D.; Delvaux N.; Brand\u00e3o-Mello C.E.; Nunes E.P.; de Sousa P.S.F.; de Souza Rodrigues L.L.L.X.; Lampe E.; do Amaral Mello F.C.; Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1. Clin Res Hepatol Gastroenterol 2019,43(6),700-706","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.antiviral.2015.01.003","volume":"116","author":"Sarrazin C.","year":"2015","unstructured":"Sarrazin C.; Lathouwers E.; Peeters M.; Daems B.; Buelens A.; Witek J.; Wyckmans Y.; Fevery B.; Verbinnen T.; Ghys A.; Schlag M.; Baldini A.; De Meyer S.; Lenz O.; Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res 2015,116,10-16","journal-title":"Antiviral Res"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"8988","DOI":"10.1038\/s41598-018-26862-y","volume":"8","author":"Bertoli A.","year":"2018","unstructured":"Bertoli A.; Sorbo M.C.; Aragri M.; Lenci I.; Teti E.; Polilli E.; Di Maio V.C.; Gianserra L.; Biliotti E.; Masetti C.; Magni C.F.; Babudieri S.; Nicolini L.A.; Milana M.; Cacciatore P.; Sarmati L.; Pellicelli A.; Paolucci S.; Crax\u00ec A.; Morisco F.; Palitti V.P.; Siciliano M.; Coppola N.; Iapadre N.; Puoti M.; Rizzardini G.; Taliani G.; Pasquazzi C.; Andreoni M.; Parruti G.; Angelico M.; Perno C.F.; Cento V.; Ceccherini-Silberstein F.; Andreone P.; Baldanti F.; Barbarini G.; Boccaccio V.; Boglione L.; Bolis M.; Bonora S.; Borghi V.; Brancaccio G.; Bruno S.; Bruzzone B.; Calvaruso V.; Caporaso N.; Ciaccio A.; Ciancio A.; Colombatto P.; Cozzolongo R.; D\u2019Ambrosio C.; D\u2019Ettorre G.; De Leonardis F.; De Luca A.; Di Biagio A.; Di Perri G.; Francioso S.; Gaeta G.B.; Gasbarrini A.; Ghisetti V.; Giorgini A.; Grieco A.; Gubertini G.; Gulminetti R.; Lambiase L.; Landonio S.; Lichtner M.; Maida I.; Marenco S.; Marinaro L.; Maserati R.; Melis M.; Menzaghi B.; Meregalli E.; Micheli V.; Niero F.; Paoloni M.; Pieri A.; Rendina M.; Romagnoli D.; Rossetti B.; Ruggiero T.; Sangiovanni V.; Starace M.; Sticchi L.; Tarquini P.; Toniutto P.; Vullo V.; Zazzi M.; Network H.C.V.V.I.R.; Prevalence of single and multiple natural NS3, NS5A and NS5B resistance-associated substitutions in hepatitis C virus genotypes 1-4 in italy. Sci Rep 2018,8(1),8988","journal-title":"Sci Rep"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/jac\/dkr581","volume":"67","author":"Vicenti I.","year":"2012","unstructured":"Vicenti I.; Rosi A.; Saladini F.; Meini G.; Pippi F.; Rossetti B.; Sidella L.; Di Giambenedetto S.; Almi P.; De Luca A.; Caudai C.; Zazzi M.; Naturally occurring hepatitis C virus (HCV) NS3\/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. J antimicrob chemother 2012,67(4),984-987","journal-title":"J antimicrob chemother"},{"key":"ref=63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221231","volume":"14","author":"P\u00e9rez A.B.","year":"2019","unstructured":"P\u00e9rez A.B.; Chueca N.; Mac\u00edas J.; Pineda J.A.; Salmer\u00f3n J.; Rivero-Ju\u00e1rez A.; Hidalgo-Tenorio C.; Espinosa M.D.; T\u00e9llez F.; Von-Wichmann M.\u00c1.; Omar M.; Santos J.; Hern\u00e1ndez-Quero J.; Ant\u00f3n J.J.; Collado A.; Lozano A.B.; Garc\u00eda-Deltoro M.; Casado M.; Pascasio J.M.; Selfa A.; Rosales J.M.; De la Iglesia A.; Arenas J.I.; Garc\u00eda-Bujalance S.; R\u00edos M.J.; Bernal E.; Mart\u00ednez O.; Garc\u00eda-Herola A.; V\u00e9lez M.; Rinc\u00f3n P.; Garc\u00eda F.; Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort. PLoS One 2019,14(8)","journal-title":"PLoS One"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.31557\/APJCP.2019.20.8.2311","volume":"20","author":"Nejabat N.","year":"2019","unstructured":"Nejabat N.; Hosseini S.Y.; Sarvari J.; Gorzin A.A.; Fattahi M.R.; Rasoolian M.; The investigation of drug resistance substitutions in ns3 protease sequence of hepatitis C virus from non-responder patients. Asian pac j cancer prev 2019,20(8),2311-2317","journal-title":"Asian pac j cancer prev"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","volume":"385","author":"Lawitz E.G.","year":"2015","unstructured":"Lawitz E.G.; Edward J; Pearlman Brian; Tam Edward; Ghesquiere Wayne; Guyader Dominique; Alric Laurent; Bronowicki Jean-Pierre; Lester Laura; Sievert William; Ghalib Reem; Balart Luis; Fredrik Lagging; Martin Dutko; Frank Shaughnessy; Melissa Hwang; Peggy Howe; Anita Y M; Wahl Janice; Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with prev. The Lancet 2015,385(9973),1075-1086","journal-title":"The Lancet"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"856","DOI":"10.4254\/wjh.v10.i11.856","volume":"10","author":"Salmon D.","year":"2018","unstructured":"Salmon D.; Trimoulet P.; Gilbert C.; Solas C.; Lafourcade E.; Chas J.; Piroth L.; Lacombe K.; Katlama C.; Peytavin G.; Aumaitre H.; Alric L.; Bou\u00e9 F.; Morlat P.; Poizot-Martin I.; Billaud E.; Rosenthal E.; Naqvi A.; Miailhes P.; Bani-Sadr F.; Esterle L.; Carrieri P.; Dabis F.; Sogni P.; Wittkop L.; Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV\/HCV coinfected patients. World j hepatol 2018,10(11),856-866","journal-title":"World j hepatol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.jhep.2021.03.004","volume":"74","author":"Sarrazin C.","year":"2021","unstructured":"Sarrazin C.; Treatment failure with DAA therapy: Importance of resistance. J Hepatol 2021,74(6),1472-1482","journal-title":"J Hepatol"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.str.2018.07.004","volume":"26","author":"Matthew A.N.","year":"2018","unstructured":"Matthew A.N.; Leidner F.; Newton A.; Petropoulos C.J.; Huang W.; Ali A.; Molecular mechanism of resistance in a clinically significant double-mutant variant of HCV NS3\/4A Protease. Structure (London, England 2018,26(10),1360-1372","journal-title":"Structure (London, England"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/v11010003","volume":"11","author":"Esposito I.","year":"2018","unstructured":"Esposito I.; Marciano S.; Haddad L.; Galdame O.; Franco A.; Gadano A.; Flichman D.; Trinks J.; Prevalence and factors related to natural resistance-associated substitutions to direct-acting antivirals in patients with genotype 1 hepatitis C virus infection. Viruses 2018,11(1),3","journal-title":"Viruses"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1021\/acschembio.5b00647","volume":"11","author":"Soumana D.I.","year":"2016","unstructured":"Soumana D.I.; Kurt Yilmaz N.; Prachanronarong K.L.; Aydin C.; Ali A.; Schiffer C.A.; Structural and thermodynamic effects of macrocyclization in HCV NS3\/4A Inhibitor MK-5172. ACS chem biol 2016,11(4),900-909","journal-title":"ACS chem biol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1128\/AAC.02929-15","volume":"60","author":"Serre S.B.N.","year":"2016","unstructured":"Serre S.B.N.; Jensen S.B.; Ghanem L.; Humes D.G.; Ramirez S.; Li Y-P.; Krarup H.; Bukh J.; Gottwein J.M.; Hepatitis C.; Hepatitis c virus genotype 1 to 6 protease inhibitor escape variants: in vitro selection, fitness, and resistance patterns in the context of the infectious viral life cycle. Antimicrob agents chemother 2016,60(6),3563-3578","journal-title":"Antimicrob agents chemother"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"6202","DOI":"10.1074\/jbc.M116.772996","volume":"292","author":"Guo Z.","year":"2017","unstructured":"Guo Z.; Black S.; Hu Y.; McMonagle P.; Ingravallo P.; Chase R.; Curry S.; Asante-Appiah E.; Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3\/4A protease from genotype 1a. J Biol Chem 2017,292(15),6202-6212","journal-title":"J Biol Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"7426","DOI":"10.1128\/AAC.01953-15","volume":"59","author":"Jensen S.B.","year":"2015","unstructured":"Jensen S.B.; Serre S.B.N.; Humes D.G.; Ramirez S.; Li Y-P.; Bukh J.; Gottwein J.M.; Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of protease inhibitor resistance. Antimicrob agents chemother 2015,59(12),7426-7436","journal-title":"Antimicrob agents chemother"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jcv.2011.08.015","volume":"52","author":"Susser S.","year":"2011","unstructured":"Susser S.; Vermehren J.; Forestier N.; Welker M.W.; Grigorian N.; F\u00fcller C.; Perner D.; Zeuzem S.; Sarrazin C.; Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J clin virol 2011,52(4),321-327","journal-title":"J clin virol"},{"key":"ref=75","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.10.046","author":"Liu Z.","year":"2019","unstructured":"Liu Z.; Mao X.; Wu J.; Yu K.; Yang Q.; Suo C.; Lu M.; Jin L.; Zhang T.; Chen X.; World-wide prevalence of substitutions in hcv genome associated with resistance to direct-acting antiviral agents. Clin gastroenterol hepatol 2019","journal-title":"Clin gastroenterol hepatol"}],"container-title":["Current HIV Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/194576","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/194576\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/194576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T10:27:16Z","timestamp":1640168836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/194576\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566523221666210707142838","relation":{},"ISSN":["1570-162X"],"issn-type":[{"value":"1570-162X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-11-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}